The Effect of Renal Function on the Pharmacokinetics of RO4995855 (Parent of ProDrug RO5024048) Following Multiple Oral Dose Administration of RO5024048
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Mericitabine (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Roche
- 18 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2010 Planned end date changed from 1 Oct 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.
- 09 Apr 2010 New source identified and integrated (ClinicalTrials.gov; NCT01099904).